Pfizer (PFE) Current Deferred Revenue (2020 - 2025)

Pfizer has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $784.0 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 48.11% year-over-year to $784.0 million; the TTM figure through Dec 2025 stood at $784.0 million (down 48.11% YoY), while the FY2025 annual figure was $784.0 million, down 48.11% from the prior year.
• Current Deferred Revenue slipped to $784.0 million in Q4 2025, from $924.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for PFE reached as high as $6.2 billion in Q4 2022 and fell as low as $784.0 million in Q4 2025.
• The 5-year median for Current Deferred Revenue is $2.4 billion (2023), against an average of $2.4 billion.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue surged 175.56% — and 2023, when it sank 66.19%.
• A 5-year view of Current Deferred Revenue shows it stood at $3.1 billion in 2021, then decreased by 17.84% to $2.5 billion in 2022, then grew by 7.14% to $2.7 billion in 2023, then sank by 44.04% to $1.5 billion in 2024, then tumbled by 48.11% to $784.0 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $784.0 million, $924.0 million, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.